Xience

Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position

Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter ABBOTT PARK, Ill., June 23 /PRNewswire-FirstCall/ -- Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System f...

Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials

Company Enrolls First Patient into SPIRIT PRIME Trial in the United States ABBOTT PARK, Ill., June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company's next-generation XIENCE PRIME(TM) E...

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study

Safety and Efficacy Rates in Patients with Challenging Anatomy Consistent with Superior Results from Randomized Clinical Trials BARCELONA, Spain, May 21 /PRNewswire-FirstCall/ -- New data presented today at EuroPCR from an international, post-approval, single-arm study show that Abbott's mark...

Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels

ABBOTT PARK, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The 2.25 mm stent system would offer physicians an option for treat...

Spirit II explores long-term performance of XIENCE V stent

CHICAGO, Ill. (March 31, 2008) Early results of the SPIRIT II study showed that the XIENCE V stent was superior to the Taxus stent in six-month findings on angiography and trended better on one-year clinical outcomes. Now, a new analysis shows that after two years, the investigational everolimus-...

Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009

...3.0 percent driven by the continued success of the xience V(R) drug-eluting stent (DES). Worldwide ph... U.S. regulatory approval and received CE Mark for xience PRIME(TM), both ahead of the company's forecast. ... Initiated Trial of Next-Generation xience PRIME(TM) Drug-Eluting Stent: Announced CE Mark f...

Newest Coated Stent Does Well in Real-World Trial

...eal-life trial, Dutch cardiologists report. The xience stent -- a flexible metal-mesh tube coated with th...he trial compared the outcomes of 649 people given xience stents with individuals who previously had stents ...sis (new blockage of the artery) was lower for the xience group than for those with bare-metal stents and sl...

Abbott Announces EuroPCR 2009 Activities

...ew data to be presented on Abbott's market-leading xience V(R) stent - Educational information available on xience PRIME(TM), Abbott's next-generation drug eluting s..., single-arm study of the company's market-leading xience V(R) Everolimus Eluting Coronary Stent System, as ...

Boston Scientific Announces Schedule for EuroPCR 2009

.../119. SPIRIT V is a post-approval registry of the xience V(R) (PROMUS(R)) Stent. ...affiliates. The PROMUS Stent is a private-labeled xience V Everolimus-Eluting Coronary Stent System manufac...d by Abbott and distributed by Boston Scientific. xience is a trademark of Abbott. The SPIRIT Clinical Pro...

Abbott Annual Meeting Highlights Outstanding 2008 Results, Continued Strong Outlook

... (adalimumab) - psoriasis and juvenile rheumatoid arthritis. Abbott also received approval in Japan for HUMIRA to treat rheumatoid arthritis. xience V(TM) drug-eluting stent in the U.S. In Abbott's cholesterol management franchise, the U.S. approval of TRILIPIX(TM) (fenofibric acid), the fi...

Xience in Medical Technology

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an 88 Percent Reduction in the Risk of Cardiac Death at Three Years ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Long-term data presen...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

ABBOTT PARK, Ill., Jan. 26 /PRNewswire-FirstCall/ -- Data published online today in Circulation from the SPIRIT III U.S. pivotal trial evaluating the XIENCE V(TM) Everolimus Eluting Coronary Stent System demonstrated that Abbott's market-leading XIENCE V outperforms the TAXUS(R) Express2(TM)...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a Repeat Procedure Compared to TAXUS(R) at Two Years WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent meta-analysis ...

SPIRIT II Explores Long-Term Performance of XIENCE V Stent

Everolimus-coated stent may hold clinical edge over Taxus stent at two years CHICAGO, March 31 /PRNewswire/ -- Early results of the SPIRIT II study showed that the XIENCE V stent was superior to the Taxus stent in six-month findings on angiography and trended b...

Abbott's Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial

- XIENCE V Demonstrates Superiority in Primary Endpoint of In-Segment Late Loss, Non-Inferiority in Major Secondary Endpoint of Target Vessel Failure and Superiority in Major Adverse Cardiac Events (MACE) in the SPIRIT III U.S. Trial - ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ -- Da...

Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials

SPIRIT FIRST Demonstrates Continued Safety for XIENCE V with No Late Stent Thrombosis or Additional Major Adverse Cardiac Events Out to Three Years BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Three-year data from the SPIRIT FIRST trial demonstrated no additional Major Adverse Cardiac ...

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent

...nly and are not available for sale. The PROMUS Stent is a private-labeled xience V(R) Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. xience V is a trademark of the Abbott Laboratories group of companies. Boston Sc...

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

... use in patients with diabetes. The PROMUS Stent is a private-labeled xience V(R) Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. xience V is a trademark of the Abbott Laboratories group of companies. Cypher is ...

Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms

...as completed enrollment. Both Element(TM) stents are expected to be approved in Europe later this year." The PROMUS Stent is a private-labeled xience V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. XIENCE V is a trademark of Abbott Laboratories...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

...ic Protection System for carotid stenting; and the xience PRIME(TM) Everolimus Eluting Coronary Stent System... the proven performance of Abbott's market-leading xience V(R) Everolimus Eluting Coronary Stent System. Onmilink Elite, EMBOSHIELD NAV6 and xience PRIME are investigational devices and are not avai...

Xience in Biological Technology

Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award

Fourth Innovation Award for Abbott in Six Years Recognizes Breakthrough Treatment for the Most Common Form of Heart Disease ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott today announced it has received a 2008 Chicago Innovation Award for its XIENCE V(TM) Everolimus Eluting Coronar...

Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent

XIENCE V USA Study to Evaluate Treatment of Coronary Artery Disease Patients in Real-World Setting ABBOTT PARK, Ill., July 9 /PRNewswire-FirstCall/ -- Abbott today announced the start of the XIENCE V(TM) USA post-approval study, with six hospital centers already recruitin...

Prix Galien USA Announces 2009 Final Candidates

... Tibotec, INTELENCE(TM) United Therapeutics, REMODULIN(R) Wyeth, Prevnar (R) Best Medical Device: Abbott Vascular, xience (R) Boston Scientific, TAXUS (R) DCA Design, Lantus(R)( )SoloSTAR(R) GlaxoSmithKline, Veramyst(R)( )Mistpro(TM) Veridex, CellS...

Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent

... newer TAXUS Liberte stent) was used as the control against the Xience(TM) V Everolimus-Eluting Coronary Stent System in the SPIRIT II and III trials. xience is a trademark of the Abbott Laboratories group of companies. The TAXUS Liberte Stent is not available for sale in Japan, where it is undergoing reg...

Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System

...t. Boston Scientific's PROMUS Stent and Abbott's xience V Stent are identical products sold by the respect...ting stent technologies with Abbott, including the xience V Everolimus-Eluting Coronary Stent System (market...f Boston Scientific Corporation or its affiliates. xience is a trademark of the Abbott Laboratories group of...

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent

... xience V, Only Drug Eluting Stent to Demonstrate Superior...stem for the treatment of coronary artery disease. xience V is the only drug eluting stent to have demonstra...em in two randomized head-to-head clinical trials. xience V will be launched in the United States immediatel...

Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline

...e processing and reagent management. -- Abbott expects to launch its XIENCE(TM) V drug-eluting stent in the United States in the second quarter. xience V was launched in Europe and other international markets beginning in late 2006. -- A controlled-release form of Abbott's pain reliever Vicodin w...

Boston Scientific Announces Schedule for ACC 2008

...signed to obtain CE Mark approval for both the xience V and PROMUS Stents. The PROMUS Stent is a private-labeled xience V Everolimus-Eluting Coronary Stent System man...f Boston Scientific Corporation or its affiliates. xience is a trademark of Abbott. The SPIRIT Clinical Prog...

Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents

...onfirmed earlier positive clinical results for the xience V (PROMUS) Stent. This trial compared xience V (PROMUS) with the market-leading TAXUS(R) Expres...f Boston Scientific Corporation or its affiliates. xience is a trademark of the Abbott Laboratories group of...

Tryton Medical Receives CE Mark Approval for its Side-Branch Stent

...ios Heart Centrum, Siegburg DE). When the Tryton cobalt chromium Bare Metal Stent was used with a standard drug eluting stent (Cypher Select, Taxus or xience V), no side branch restenosis was observed in the 30 patients treated. The initial core laboratory quantitative analysis reported a late loss of 0.27 ...